To accomplish effective cancer imaging and integrated therapy, the multifunctional nanotheranostic Fe3O4-MTX@HBc core-shell nanoparticles (NPs) were designed. A straightforward method was demonstrated for efficient encapsulation of magnetic NPs into the engineered virus-like particles (VLPs) through the affinity of histidine tags for the methotrexate (MTX)-Ni 2+ chelate. HBc144-His VLPs shell could protect Fe3O4-MTX NPs from the recognition by the reticuloendothelial system as well as could increase their cellular uptake efficiency. Through our well-designed tactic, the photothermal efficiency of Fe3O4 NPs were obviously improved in vitro and in vivo upon near-infrared (NIR) laser irradiation. Moreover, Magnetic resonance imaging (MRI) results showed that the Fe3O4-MTX@HBc core-shell NPs were reliable T2-type MRI contrast agents for tumor imaging. Hence the Fe3O4-MTX@HBc core-shell NPs may act as a promising theranostic platform for multimodal cancer treatment.
Introduction
Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer. However, the current chemotherapeutic agents have many adverse effects on healthy tissues or normal cells. 1 Continuing improvement in the tumor specific multifunctional nanoparticles for targeting and efficient delivery of drugs to tumor cells is an area of intense research with the potential to revolutionize the treatment of cancer. 2, 3 Recently, the combination of photothermal and chemotherapy is widely applied in killing cancer cells by using nanoparticles, such as nanosized graphene oxide, 4 gold nano particles, 5 plasmonic copper sulfide nanocrystals, 6 folate-lipid-poly(lacticco-glycolic acid) lipid-polymer nanoparticles 7 and so on.
As a major class of nanoparticles, magnetic nanoparticles have been examined extensively for applications in cancer therapy due to their ultra-small size, biocompatibility and magnetic properties. 8, 9 More recently, clustered Fe3O4 magnetic nanoparticles have been reported to possess broad optical
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International Publisher absorption in the near-infrared (NIR) range and have further been used as a class of photosensitizers for tumor photothermal therapy (PTT). 10 Compared with other photosensitive nanomaterials, Fe3O4 nanoparticles possess various advantages, such as: 1) superior biocompatibility; 2) biodegradability (Fe3O4 nanoparticles can be degraded into iron ions in vivo and excess iron ions can be transferred into ferritin proteins for iron storage and detoxification), and 3) good superparamagnetic properties make them as excellent contrast agents for magnetic resonance imaging (MRI). 11, 12 However, due to the easy agglomeration and the limited functional groups of Fe3O4 nanoparticles, a suitable material coating, such as silica, polyethylene glycol (PEG), bovine serum albumin (BSA) and so on, is always necessary to improve the situations and is of significance for bioapplications. [13] [14] [15] Lately, virus-like particles have attracted much attentions because of their potential to be a new drug delivery system for clinical therapy. 16 The VLPs are multimeric protein assemblies that can serve as robust synthetic carriers due to the ability to encase nucleic acids or other small molecules by self-assembling in proper conditions. 17 The protein shells of VLPs are steady to protect the cargos from quick releasing in blood circulation and can be chemically and genetically readily modified by genetic engineering or chemical methods. 18 The size of VLPs are commonly between 18 -100 nm in diameter, makes them easily internalized by cells and biodegradable with extremely low cytotoxicity. The VLPs exhibit the potential to be a safe drug delivering system. 19 VLP-based core-shell nanoparticles have been widely applied in biomedical applications. For example, Zhang Y. et al. have prepared quantum dots (QDs) loaded HIV-1 based lentivirus for tracking virus infection. 20 Fang PY. et al. have encapsulated functional RNAs into bacteriophage Qβ VLPs to attenuate cell proliferation and promote mortality of brain tumor cells. 21 Moreover, Li C. et al. have constructed Ag2S QDs loaded simian virus 40 VLPs for real-time in vivo NIR-II imaging. 22 However, the integrated single function of the developed VLPs based core-shell nanoparticles limited their efficacy for tumor imaging and therapy. Therefore, it is vital to develop multifunctional VLPs based nanoprobes for tumor imaging and therapy.
The hepatitis B virus core antigen (HBc) could spontaneously assemble into an icosahedral particle in all viable prokaryotic and eukaryotic recombinant expression systems. 23 Herein, we designed and developed a novel magnetic drug delivery system (Fe3O4-MTX@HBc), in which MTX was chemically conjugated to Fe3O4 nanoparticles and subsequently embedded into a shell of hepatitis B virus core protein (HBc) VLPs. As a natural nanocarrier, HBc presented empty interior space that can enhance the stability and biocompatibility of the nanodrugs. Moreover, the HBc VLPs can be easily modified with functional groups using the methods of genetic or chemical engineering. [24] [25] [26] Owing to these merits, HBc VLPs can be a promising candidate as nanocarriers.
The detailed synthetic procedures and potential applications for this drug delivery system were illustrated in Scheme 1. The multifunctional Fe3O4-MTX NPs still hold the photothermal and magnetic properties after modified MTX on the surface. The viral nature and the essence of protein of HBc144-His VLPs could facilitate the internalization of Fe3O4-MTX by the cancer cells. The presence of VLPs shell could also provide a protective layer for drug molecules and magnetite nanoparticles from the recognition by the reticuloendothelial system, therefore allowing drugs to be administered over prolonged periods.
Materials and Methods

Materials
Ferric chloride (FeCl3), anhydrous sodium acetate (NaOAc), and hexahydrate nickel chloride (NiCl2·6H2O) were purchased from Shantou Xilong Chemical Factory (Guangdong, China). Dimercaptosuccinic acid (DMSA), phosphotungstic acid (TPA), dicyclohexyl carbodiimide (DCC) and MTX were purchased from Sigma-Aldrich (ST. Louis, USA), N-hydroxysuccinimide (NHS) were purchased from Solarbio (Beijing, China). Diethylene glycol (DEG), glycerol, and dimethyl sulfoxide (DMSO) were purchased from Sinopharm Chemical Reagent Co. Ltd.
(Shanghai, China). Urea, glycine, tris(hydroxymethyl) aminomethane (Tris), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and Annexin V-FITC/PI Apoptosis Detection Kit were purchased from KeyGen Biotech Co. Ltd. (Nanjing, China). RPMI 1640 culture medium and penicillin-streptomycin were purchased from Biological Industries (Beit Ahemeq, Israel). Fetal bovine serum (FBS) and trypsin were purchased from Invitrogen (California, USA). All chemicals were used without further purification. Ultrapure water (18.2 MΩ·cm) were obtained from Milli-Q Water Purification System.
Preparation and characterization of Fe3O4 and Fe3O4-MTX@HBc
Synthesis of Fe3O4-MTX-Ni 2+ nanocomposites Fe3O4 NPs were prepared according to a former literature method. 27 DMSA modified Fe3O4 NPs (11.7±1.6 nm in diameter) were obtained by the procedure as previously described. 28 240 mg of the as-prepared Fe3O4-DMSA NPs were firstly re-dispersed in 20 ml of DMSO. 400 mg of DCC and 400 mg of NHS were then added and stirred for 30 min before magnetic separation. 24 mg of MTX and 24 ml of DMSO were added to the precipitation and stirred for 12 h before magnetic separation. The addition of DCC and NHS to the Fe3O4-DMSA could form a highly reactive intermediate (NHScarboxylate), which could subsequently react with the free amino group on MTX. 29 The supernatant was collected to determine unloaded MTX and subsequently to calculated the drug loading efficiency (%, w/w). Afterwards, Fe3O4-MTX-Ni 2+ complexes were acquired by mixing 23 mg of Fe3O4-MTX NPs with 240 mg of NiCl2 (0.1 M aqueous solution) for 30 min and finally extracted by magnetic separation.
Preparation of Fe3O4-MTX@HBc NPs
HBc144-His VLPs were prepared following the method from our former research with minor modifications 28 . In brief, HBc144-His VLPs were produced by Escherichia coli expression system and purified by ion-exchange column chromatography and molecular sieve chromatography. Herein, 23 mg of HBc144-His VLPs were disassembled after incubating with 15 ml of the denaturant stock solution (2.5 M urea, 150 mM NaCl and 50 mM Tris-HCl) at 4 o C for 30 min. 23 mg of Fe3O4-MTX-Ni 2+ was then added into the denaturant solution containing HBc144-His subunits and vortexed at 4 o C for 10 min.
The reassembly of VLPs was initiated at 4 o C by dialyzing the dissociated HBc144-His subunits in an assembling buffer A (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% v/v glycerol, 1% w/v glycine). After 12 h, the dialysate was replaced by assembling buffer B (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% w/v glycine) and dialyzing for another 12 h. The Fe3O4-MTX-Ni 2+ -containing VLPs (Fe3O4-MTX@HBc) were finally acquired by magnetic separation and lyophilization (-20 o C, 12 h).
Characterization
The hydrodynamic radius of Fe3O4-MTX@HBc was determined by dynamic light scattering (DLS) measurements using Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worchestershire, U.K.). Morphology and structure of the prepared NPs were characterized by a transmission electron microscopy (TEM, Tecnai G2 Spirit, FEI, USA) after the samples were negatively stained using 2 % TPA. Powder X-ray diffraction (XRD) patterns were collected using a German Bruker-axs D8-A25 X-ray diffractometer. The fourier transform infrared spectra (FT-IR) were recorded on a Fourier transform infrared spectroscope (Nicolet IS10, Thermo Fisher Scientific, USA). The drug loading efficiency of MTX in Fe3O4-MTX NPs was determined by high performance liquid chromatography (HPLC, separations module 2695, photo diode array detector 2996, Waters, USA). Photothermal experiments were conducted using an infrared reflector lamp (Hi-Tech optoelectronics, China) with a power density of 1.5 W·cm -2 . The temperature and thermal images were collected by infrared thermal camera (FLIR A35, FLIR, Sweden). A vibration sample magnetometer (Lake Shore 7404, Lake shore, USA) was used to measure the magnetic properties of the as-prepared samples. The concentration of Fe 3+ was determined by inductively coupled plasma mass spectrometry (ICP-MS, 7500 CE, Agilent, USA). -1 ) and equal amount of Fe3O4-MTX NPs for 1 h, 2 h and 3 h, respectively. The cells were harvested and washed with PBS to remove the free NPs. Then 10 7 cells were suspended in 0.1% agarose for in vitro MRI. The testing parameters were adopted: TR= 2500 ms, TE= 11 ms, matrix size = 256 × 256, slice thickness = 1 mm, and FOV = 40 × 40.
T2-weighted MRI of Fe3O4 -MTX@HBc
In the T2-weighted MRI of tumors in vivo, the murine breast cancer 4T1 subcutaneous xenograft tumor bearing mice (tumor size: ~ 400 mm 3 ) were used. The MRI were performed before and after 30 min post of the intratumoral injection of Fe3O4-MTX@HBc (100 μL, 4 mg·mL -1 ). The transverse plane MR images were acquired using the following parameters: TR = 2000 ms, TE = 60 ms, matrix size = 128 × 128, slice thickness = 2 mm, and FOV = 40 × 40.
In Vitro Photothermal effect of Fe3O4-MTX@HBc NPs
The murine breast cancer 4T1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units·mL -1 penicillin and 0.1 mg·mL -1 streptomycin, at 37 o C in 5% CO2. After 4 h of incubation with Fe3O4-MTX@HBc NPs (200 μg·mL -1 ) or normal medium (control), the cells were collected in vials. The cell pellets were irradiated for 5 min with an 808 nm laser at a power of 2 W·cm -2 (facula 0.5 cm). The temperature and thermal images were collected with an infrared thermal camera (FLIR A35, FLIR, Sweden). After the cells were seeded in 96-well plates with 5000 cells/well and cultured for 12 h, Fe3O4-MTX@HBc NPs with different concentrations (25, 50, 100, 200 , and 300 μg·mL -1 ) were added to the wells, respectively. For photothermal treatments, the cells were treated with 5 min of irradiation of 808 nm laser light at power density (2 W·cm -2 , facula 1.5 cm). After the cells were incubated at 37 o C for 24 h, 20 μL of MTT (5 mg·mL -1 in PBS) was added into each well and incubated for another 4 h. The medium in each well was replaced by 200 μL of DMSO after the 4 h of incubation, and the plates were gently shaken for 0.5 h to dissolve the formazan precipitate. The cells were followed by determining absorbance at 490 nm using a spectrophotometric microplate reader (Infinite 200 pro, Tecan, Switzerland).
4T1 cells were seeded in 12 well plates at 1×10 5 cells per well. After 12 h of incubation, 200 μg·mL -1 of Fe3O4-MTX@HBc NPs was added to cells for another 6 h of incubation before exposed to NIR laser (808 nm, 2 W·cm -2 ) for 5 min. Cells incubated with normal medium were used as control group. Annexin V-FITC/PI Apoptosis Detection Kit was used to analyze cell apoptosis by flow cytometry (BD Accun, Becton Dickinson Medical Devices, USA) after 12 h of incubation followed by the standard protocols.
In Vivo Biodistribution analysis of Fe3O4-MTX@HBc NPs
For in vivo biodistribution analysis, 100 μL of Fe3O4-MTX@HBc and Fe3O4-MTX NPs (both amount of 12 mg·kg -1 ) were separately intratumorally injected into the murine breast cancer 4T1 subcutaneous xenograft tumor bearing mice (tumor size: 150-200 mm 3 ). The mice were sacrificed after 2 h of injection and the Fe 3+ ions content of tissues (including heart, liver, spleen, lung, kidney, brain and tumors) were measured by inductively coupled plasma mass spectrometry (ICP-MS, 7500CE, Agilent, USA).
In Vivo Photothermal Therapy of tumor
The BALB/c mice were purchased from Beijing Vital River Laboratories Animal Technology Co. Ltd. and were taken care of under Institutional Animal Care and Use Committee of Xiamen University. 0.1 mL of 4T1 cell suspension (1×10 6 ) was subcutaneously injected to the mice (6 -8 week). When the tumor size was up to 150 -200 mm 3 , the mice were intratumorally injected with or without 100 μL of Fe3O4-MTX@HBc NPs (12 mg·kg -1 ).
For in vivo PTT, the tumors were irradiated by 808 nm NIR laser (1.5 W·cm -2 , facula 1.0 cm) for 5 min. The real-time temperature and infrared thermal images of the tumor sites were recorded by an infrared thermal camera (FLIR A35, FLIR, Sweden).
For in vivo therapeutic efficacy, the growth rate of tumors was investigated by monitoring the tumor volumes (as calculated by the formula (1)) and body weight of mice per day.
V= a×b 2 /2 (1) Where a and b indicated the longest diameter and the shortest diameter, respectively. The tumors were photographed during the therapy period. The mice were euthanized on 10 th day to detach the tissues (including heart, liver, spleen, lung, kidneys and tumors) and followed by further histological examinations using the hematoxylin and eosin (H&E) staining.
Results and Discussion
Preparation of Fe3O4 -MTX NPs
To facilitate the efficient encapsulation in HBc144-His VLPs, monodispersed Fe3O4 NPs with a size of 10 -15 nm were prepared (Fig. S1A) . XRD patterns demonstrated the successful synthesis of Fe3O4 (Fig. S1B) . For combination of PTT with chemotherapy, MTX was conjugated to the surface of Fe3O4 NPs via the covalent attachment between MTX and DMSA functionalized Fe3O4 NPs. FT-IR spectra were collected to prove the existence of amido bond (Fig. S2A) . The magnetic property of MTX modified Fe3O4 NPs was measured and then displayed by magnetic hysteresis loop (Fig. S2B) . The measurement showed that Fe3O4-MTX NPs owned a saturation magnetization value (Ms) of 9.1 emu·g -1 . The drug loading efficiency of MTX in Fe3O4-MTX NPs was determined at 3.4%.
Preparation of Fe3O4 -MTX@HBc NPs
In order to efficiently encapsulate the Fe3O4-MTX NPs into VLPs, HBc-144-His VLPs were engineered interiorly possessing histidine tags by genetic engineering to attract the Fe3O4-MTX-Ni 2+ chelate during the process of encapsidation. 29 The HBc144-His VLPs were obtained from E.coli. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to yield a single band corresponding to molecular weight of 14 kDa, indicating the corresponding molecular weight (14 KDa) of HBc144-His subunit (Fig. 1A) .
To increase the dispersibility and biocompatibility of Fe3O4-MTX NPs under biological conditions, monodispersed Fe3O4-MTX@HBc NPs were prepared by encapsulating Fe3O4-MTX NPs into HBc144-His VLPs. Morphology of Fe3O4-MTX@HBc NPs was confirmed by TEM image (Fig. 1B) . The shells were formed regularly by the composition of HBc144-His units. The Fe3O4-MTX cores inside the NPs presented much darker color than the protein shells. The analogous core-shell structure of Fe3O4@HBc VLPs has been demonstrated by atom force microscopy (AFM) and magnetic force microscopy (MFM) in our previous work. 28 The encapsulation efficiency of Fe3O4-MTX@HBc144-His NPs could reach 89 % through counting more than 200 NPs according to the large-scale TEM images. The hydrodynamic size of Fe3O4-MTX@HBc NPs was 38.2 ± 5.6 nm measured by DLS (Fig. 1B) . Hence, the encapsulation of Fe3O4-MTX NPs into HBc144-His VLPs could yield monodispersed, well-defined, hybrid nanostructures and facilitate addressable functionalization of the Fe3O4-MTX NPs.
The proportion of Fe3O4-MTX in Fe3O4-MTX@HBc NPs was determined by ICP-MS, indicating that there was 0.067 mg of Fe in 1 mg of Fe3O4-MTX@HBc NPs, based on which it was calculated that there were 13.8% Fe3O4-MTX and 86.2% other contents mainly protein in the Fe3O4-MTX@HBc NPs.
Photothermal effects
In order to confirm that Fe3O4-MTX@HBc NPs could be utilized as PTT agent, the photothermal performance was investigated. Fe3O4-MTX@HBc NPs in different concentrations were exposed to 808 nm NIR laser with power density of 1.5 W·cm -2 . When 0.1 mg·mL -1 of Fe3O4-MTX@HBc NPs were exposed to NIR laser, the temperature of the suspension had an increase of 20. (Fig. 1C) . Photothermal stability of Fe3O4-MTX@HBc NPs was also investigated by 5 min of continuous irradiation followed by another 5 min of irradiation after dropping to the room temperature for three cycles. It can be visualized from the curves that there was no obvious photothermal ability change happened in 3 cycles (Fig. 1D) . After NIR laser irradiation, Fe3O4-MTX@HBc NPs still exhibited good dispersion in PBS, indicating that Fe3O4-MTX@HBc NPs have an excellent photothermal stability and great potential for use in thermal therapy.
In Vitro Photothermal-Chemo Therapy of Fe3O4 -MTX@HBc NPs
To investigate the in vitro photothermal effect of Fe3O4-MTX@HBc NPs, 4T1 cells were treated by Fe3O4-MTX@HBc NPs and NIR laser. The thermal images of 4T1 cell pellet were shown in Fig. 2A and the curves of cell pellet temperature versus time were shown in Fig. 2B . The temperature for cells treated by Fe3O4-MTX@HBc NPs increased to 50.6 o C, which was much higher than that for untreated cells (36. and all experiments evidenced an increasing cytotoxicity against 4T1 cells in a dose-dependent manner, revealing that the attachment of MTX to Fe3O4 NPs did not influence the chemo cytotoxicity of MTX. It presented a much higher efficacy of Fe3O4-MTX@HBc NPs to kill the tumor cells with 5 min of NIR irradiation, compared with the groups without light irradiation at all concentrations (Fig.  2C) , indicating that Fe3O4-MTX@HBc NPs can effectively improve the efficiency of killing tumor cells in vitro by combining PTT and chemotherapy.
The cytotoxicity of Fe3O4-MTX@HBc NPs with NIR irradiation was verified by Annexin V-FITC/PI staining. Only untreated cells could not produce significant cell death. For the Fe3O4-MTX@HBc NPs groups, the cells with NIR irradiation exhibited significantly more apoptosis and necrosis (80.8%) than the cells without NIR irradiation (36.2%) (Fig.  2D ). This result also confirmed the excellent synergistic effect of photothermal-chemo therapy of Fe3O4 -MTX@HBc NPs.
T2-weighted MRI capability
As a noninvasive imaging tool, MRI is now widely used in hospitals for disease diagnosis, and can provide a three-dimensional anatomical image without exposing the body to ionizing radiation. 30 Fe3O4 NPs are commonly used as MRI contrast agents because they have the ability to shorten the T2 relaxation time of surrounding water. 31 To measure the T2-weighted MRI ability of Fe3O4-MTX@HBc NPs, the MRI of the NPs were performed. It can be observed from Fig. 3A that the brightness of Fe3O4-MTX@HBc suspensions were getting lower along with the increasing concentration in the T2-weighted MR images. In the meantime, the inverse relaxation time (T2 -1 ) versus Fe concentration fitted line well and the r2 relativity values was 156 (mg·mL -1 ) -1 s -1 , indicating the potential of Fe3O4-MTX@HBc NPs to be a good T2-weighted MRI contrast agent. This might be due to that HBc VLPs could provide the advantages of proper size and shape, which can increase the chance of improving the rate of relaxation rates and the ideal modification of the contrast agent label. 32 In vitro T2-weighted MRI was performed to compare the cellular uptake efficiency of Fe3O4-MTX@HBc and Fe3O4-MTX NPs (Fig. 3B) . Comparing with the Fe3O4-MTX NPs treated group, the decrease of T2-weighted MR signal intensity and shorted T2 relaxation time were obtained after cells incubating with Fe3O4-MTX@HBc NPs for various durations. The results further demonstrated the higher cellular uptake efficiency of Fe3O4-MTX@HBc over Fe3O4-MTX NPs. This is due to that HBc144-His VLPs are a kind of biocompatible protein materials and can improve the dispersion and stability of Fe3O4-MTX under physiological conditions.
As the salient features of Fe3O4-MTX@HBc NPs, the magnetism was further evaluated in vivo on T2-weighted MRI to afford guidance for cancer therapy. As shown in Fig. 3C , the clear tumor boundary and much darker interior could be observed after injected of Fe3O4-MTX@HBc NPs. Which resulted from the decrease of T2-weighted MR signal intensity at tumor sites. Such an obvious difference in T2-weighted signal could help to find the position of tumor precisely, even the position of high-density of cancer cells. These results demonstrated that Fe3O4-MTX@HBc NPs could be used as a reliable MRI contrast agent for guiding therapy and reveal the in vivo biodistribution of themselves.
In Vivo Biodistribution analysis of Fe3O4-MTX@HBc NPs
The in vivo biodistribution of Fe3O4-MTX@HBc and Fe3O4-MTX NPs were evaluated by the Fe 3+ ions content in tissues and tumors. As shown in Fig. S3 , after intratumoral injecting nanoparticles for 2 h in mice, the tumor accumulation of Fe3O4-MTX@HBc NPs showed an enhancement of 1.39 folds than Fe3O4-MTX NPs treated group. These results were attributed to that the presence of HBc144-His VLP shell could increase the chemical stability and the dispersion of hydrophobic Fe3O4-MTX under physiological conditions, as well as could also provide a protective layer for drug molecules and magnetite nanoparticles from the recognition by the reticuloendothelial system, therefore allowing drugs to be accumulated in the tumor over the prolonged periods of time.
The mice in Fe3O4-MTX@HBc NPs treated groups (especially the one combined with PTT) exhibited remarkable delay in tumor growth or tumor regression compared to untreated group (Fig. 4C, D) , demonstrating the outstanding photothermal-chemo synergistic effect of Fe3O4-MTX@HBc NPs. No obvious weight changing was observed for all groups (Fig. 4E) . All the mice were alive during the 10 days of therapy period. In vivo toxicity of Fe3O4-MTX@HBc NPs was analyzed by H&E staining and no obvious organ damages or toxic side effects were discovered in all groups, meanwhile the apparent coagulative necrosis extensively existed in tumors in the mice of Fe3O4-MTX@HBc NPs treated groups (Fig. 5) . All the results indicated that Fe3O4-MTX@HBc NPs had strong antitumous effect in the photothermal-chemo synergistic treatment process in vivo and could be used as remarkable nanotheranostic agent for further biomedical researches and applications.
Conclusions
In this work, we developed a novel kind of multifunctional core-shell nanoparticles, which encapsulated Fe3O4-MTX NPs in HBc144-His VLPs for MRI-guided photothermal-chemo therapy of cancer. The designed Fe3O4-MTX@HBc NPs possess good monodispersity, well-defined morphology, high r2 relaxivity, good biocompatibility/biodegradation and strong NIR absorption feature. The outstanding MRI ability of Fe3O4-MTX@HBc NPs was confirmed on animals and visualized explicit effect of tumor magnetic resonance imaging. The therapeutic results of animal experiments reveal that the Fe3O4-MTX@HBc NPs present remarkable antitumor effect in combination of PTT and chemotherapy on cancer study. These excellent properties afford its applications as a theranostic nanoprobe for MRI-guided photothermal-chemo therapy of cancer.
